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Abstract: The relationship between the human papillomavirus (HPV) and malignancies of 
the uterine cervix, vagina, and vulva has been established. The development of a quadrivalent 
HPV recombinant prophylactic vaccine represents the first time in history that primary prevention 
of these cancers is offered to girls and women. The prevalence of oncogenic HPV subtypes in 
cervical cancers has been the most studied, but prevalence has also been established for vaginal 
and vulvar cancers. Clinical trials demonstrate impressive efficacy in disease prevention as well 
as excellent safety and tolerability. The role the quadrivalent HPV recombinant vaccine promises 
to have in the reduction of gynecologic malignancies will depend on various factors, including 
acceptance and accessibility of the vaccine, duration of immunity, and cross-protection against 
other oncogenic HPV subtypes. The HPV vaccine’s role in disease reduction will probably be 
viewed in the context of a strategy that involves continued secondary screening and lifestyle 
modification to reduce modifiable risk factors, along with widespread vaccination.
Keywords: human papillomavirus, quadrivalent vaccine, cervical cancer, vaginal cancer, 
vulvar cancer
Human papillomavirus (HPV)-associated gynecological cancers include cancers of 
the uterine cervix, the vagina, and the vulva. HPV-related non-genital cancers that can 
occur in either gender include anal cancer and oropharyngeal cancers. Non-malignant 
disease processes associated with HPV include genital warts and respiratory laryngeal 
papillomatosis. The understanding that many HPV-related cancers develop from 
precancerous states along with the knowledge that many of these cancers are mediated 
by similar types of high-risk oncogenic HPV has been revolutionary. The result 
of this knowledge has led to the development of prophylactic HPV vaccines. The 
quadrivalent HPV recombinant vaccine Gardasil® (Merck & Co., Inc., Whitehouse 
Station, New Jersey, USA) provides protection from 4 types of HPV: 6, 11, 16, and 18, 
and was licensed in 2006. The quadrivalent HPV recombinant vaccine was approved in 
the US by the Food and Drug Administration (FDA) for the prevention of anogenital 
warts, cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ of the cervix 
(AIS), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), 
and cervical cancer. In October 2008 the label was expanded to include vulvar and 
vaginal cancers. The bivalent prophylactic HPV Cervarix® (GlaxoSmithKline, Brent-
ford, UK) vaccine provides protection from two types of HPV (16 and 18) and was 
licensed in 2007 but has yet to be approved by the FDA in the US. Prophylactic HPV 
vaccine development is an astounding accomplishment and represents the first time in International Journal of Women’s Health 2009:1 120
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history that a vaccine has been offered to girls and women for 
prevention of gynecological cancers. Despite its importance 
in medical history, the HPV vaccine is not the first vaccine 
to protect against a viral agent with a known association to 
malignancy, this being the hepatitis B vaccine for hepatocel-
lular carcinoma.1
There are over 100 types of HPV with approximately 
35 types having affinity for the genital tract.2 HPV viruses 
are further subdivided into two divisions – those with the 
ability to promote cancers and those that do not. The former 
division is also referred to as oncogenic or high-risk while 
the latter division is referred to as non-oncogenic or low-risk. 
The high-risk oncogenic HPV types include types 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 while the 
low-risk HPV types include types 2, 3, 6, 7, 10, 11, 13, 32, 
40, 42, 43, 44, and 57. The types are related to each other 
phylogenetically, based on degree of genetic relatedness.3 
In 1995 the International Agency for Research on Cancer 
established that out of the approximately 15 types of high-
risk HPV , types 16 and 18 were responsible for about 70% 
of cervical cancers in 5 geographic regions of the world.4 
It appears that HPV types 16 and 18 make up a larger fraction 
(72% to 77%) in developed countries compared to less-
developed regions (65% to 72%).5 In a recent meta-analysis 
of HPV type-distribution in vulvar and vaginal cancers and 
their precursors, the HPV prevalence of vaginal cancers was 
found to be 65.5% while that of vulvar cancers was found to 
be 40.1%.6 In this meta-analysis, among cases of HPV-related 
vulvar and vaginal carcinoma, types 16 and 18 were the 
most common HPV types implicated. In another series that 
described prevalence and estimated attribution of HPV types 
in cervical, vaginal, and vulvar cancers it was observed that 
the proportion of any vulvar cancers testing positive for any 
HPV types was 65.3%, with HPV 16 contributing to about 
50% of all cases overall.7 Although data for vaginal cancer 
were sparse in this report, HPV 16 contributed the largest 
proportion (63.2%) of HPV-positive vaginal cancers. It is 
interesting to note that HPV types 16 and 18 have also been 
implicated in penile cancer and in non-genital HPV-related 
malignancy of the anus8 as well as in the majority of cancers 
of the oropharyngeal cavity.9 The importance of this revela-
tion is that HPV vaccines may also protect against these 
other malignancies. Low-risk HPV infections are implicated 
in genital warts and laryngeal respiratory papillomatosis. 
HPV types 6 and 11 are responsible for 90% of genital 
warts as well the majority of cases of laryngeal respiratory 
papillomatosis. The economic burden associated with non-
oncogenic HPV disease is staggering. In an analysis, the 
annual cost of conditions related to non-cervical HPV 6, 11, 
16, and 18 (including genital warts and juvenile respiratory 
papillomatosis) in the US was estimated in 2003 to average 
US$418 million.10
Cervical cancer
In women, the most studied HPV-related malignancy is 
cervical cancer. There is a dichotomy in the incidence of 
cervical cancer in developed versus developing countries of 
the world. For example, in the US, cervical cancer incidence 
had been in decline since the introduction of the Pap smear 
in the 1950s.11 In the US cervical cancer incidence in 2008 
was 11,070 with 3870 deaths.12 However, in developing coun-
tries of the world, cervical cancer represents one of the top 
two causes of cancer deaths in women.13 Sub-Saharan Africa 
and South America are regions of the world where cervical 
cancer remains an insurmountable threat to women’s health. 
Sadly the World Health Organization has predicted that by 
2050 the annual incidence of new cervical cancer cases in 
the world will be one million with the vast majority of cases 
and deaths seen in developing countries. While organized 
secondary prevention programs of Pap smear screening with 
surveillance have been successful in significantly reducing 
cervical cancer incidence and death in developed regions, a 
large portion of women in less developed regions continued to 
die unnecessarily from a preventable disease. Although many 
reasons can be cited for the lack of introduction of cervical 
cancer screening programs in these regions, the underlying 
reason is lack of resources and infrastructure due to wide-
spread poverty. It is important to realize that although HPV 
vaccines will hopefully reduce the incidence of cervical cancer, 
secondary screening programs cannot be abandoned.
It has been established that persistence of the HPV virus 
is required for the development of cervical cancer.14 The 
natural history of cervical cancer starts with infection of the 
genital tract with the virus. This occurs through skin to skin 
contact of the genital region possibly at the site of micro-
trauma. The life-cycle of the virus is integrally linked to 
maturation of the keratinocyte. Once this process has begun, 
several outcomes can occur including clearance of the virus 
or progression to precancerous states. If left unchecked, 
precancerous states can progress to cervical cancer. Risk 
factors in the development of cervical cancer include early 
age at onset of sexual activity, multiple sexual partners, 
having a high-risk sexual partner, and high parity. The HPV 
virus is cleared through competence of the immune system. 
It is not surprising therefore that the immunosuppressive 
states of HIV15 and transplant recipiency16 are also risk factors International Journal of Women’s Health 2009:1 121
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for the development of cervical cancer. In addition to the 
presence and persistence of the HPV virus, several cofactors 
are implicated in the development of cervical cancer. These 
cofactors include Chlamydia trachomatis,17 herpes simplex 
virus,18 cigarette smoking,19and oral contraceptive pills.20 
Recently it has been postulated that certain genetic variations 
in women, specifically at two locations of the TAP gene, may 
reduce the rates of immune clearance and indirectly influence 
oncogenesis by promoting persistence of HPV .21
Vaginal and vulvar cancer
The natural history of vaginal and vulvar cancer is less 
studied and complicated by several factors. The study of 
vaginal cancer is limited due to the rarity of this malignancy. 
In 2008, there were fewer than 2210 new cases annually and 
fewer than 760 deaths in the US.22 Vaginal cancers represent 
1% to 3% of gynecologic malignancies worldwide.23 In addi-
tion to the rarity of vaginal cancer, the etiology of vaginal 
cancers is mixed. Although the majority of vaginal cancers 
are squamous cell carcinomas and caused by HPV infection, 
other types of vaginal cancers include melanoma and clear 
cell adenocarcinomas which are linked to in utero maternal 
diethylstilbestrol.24 It is assumed that HPV-related vaginal 
cancer also follows a precursor state and it has been theorized 
that the rarity of vaginal cancers compared to cervical cancer 
may be related to the absence of a susceptible transformation 
zone and the protective nature of the keratinized vaginal 
mucosa. The precursor states of vaginal cancer are referred 
to as vaginal intraepithelial neoplasia (VaIN). Risk factors for 
the development of vaginal cancers include many of the same 
risk factors for the development of cervical cancers, including 
young age at first coitus, greater number of lifetime sexual 
partners, prior anogenital disease, and smoking. In a recent 
meta-analysis studying factors affecting risk of mortality from 
vaginal cancers, the mean age at diagnosis was 65.7 years 
and incidence rates of vaginal cancers were noted to increase 
with age.25 Other findings of this meta-analysis include higher 
incidence rates with lower socioeconomic status, which is also 
observed in cervical cancer incidence rates.
Vulvar carcinoma is the fourth most common gyneco-
logic malignancy in the US with an estimated 1100 new 
cases and 400 deaths annually.26 In the UK, vulvar cancer 
is ranked 18th in incidence of all malignancies in women 
with just slightly over 1000 women diagnosed yearly and 
approximately 365 deaths per year.27 In both of these 
developed countries, there is an increasing incidence of 
HPV-related vulvar cancers in the last 25 years particularly 
in younger women. Over 90% of vulvar carcinomas are 
squamous cell carcinomas. There appears to be two types 
of vulvar squamous carcinoma. The first type, also referred 
to as Bowenoid type, is associated with HPV, particularly 
HPV 16, 18, and 33.28 The other type of vulvar squamous 
cell carcinoma is associated with chronic vulvar dermatoses 
such as lichen sclerosus and lichen planus. In addition there 
are other non-HPV-related vulvar carcinomas including 
melanoma, basal cell carcinoma, sarcoma, extramammary 
Paget’s disease, and Bartholin gland adenocarcinoma.29 
Although traditionally the precancerous states of vulvar 
carcinoma were referred to as VIN, current nomenclature 
designated by the International Society for the Study of 
Vulvovaginal Disease subdivides VIN into categories asso-
ciated with HPV referred to as usual type (warty, baseloid, 
or mixoid) and into categories associated with vulvar 
dermatoses, referred to as well-differentiated type.30 The 
increase of HPV-related vulvar cancers in young women 
highlights one of the differences between the natural his-
tory of cervical cancer and vulvar cancers – the interval 
between diagnoses of VIN usual type may be expressed in 
years versus decades as is often the case in the progression 
of CIN to cervical cancer.31
Development of the HPV vaccine
The human papillomavirus is a non-enveloped, double-
stranded DNA virus. The circular HPV genome is about 
8000 nucleotides in length and the genome is divided into 
two regions: the early region and the late region. The early 
region is expressed during early parts of viral replication 
cycles and contains the codes for genes important in viral 
replication. The late region is expressed during the later part 
of viral replication cycle and contains the codes for the two 
viral capsid proteins, L1 and L2. L1 is the major protein 
and is used to make the HPV vaccines. The vaccine is made 
by isolating the DNA of the naturally occurring HPV then 
cloning the gene or open reading frame encoding the L1 
capsid protein into a plasmid. The plasmid containing the 
L1 gene is introduced into a eukaryotic cell. The L1 gene 
is transcribed into mRNA and the cell then translates the 
mRNA into L1 capsid proteins. The capsid proteins self 
assemble within the cells to form viral-like particles (VLPs). 
Because viral DNA (with the exception of the L1 gene) has 
not been introduced into the eukaryotic cell, viral genomes 
are not available to incorporate with the viral-like particles. 
This removes the danger of producing infectious virions or 
promoting cancer. After purification, the VPLs are injected 
into the host and elicit an immune response. During normal 
genital HPV infections, the primary immunologic response International Journal of Women’s Health 2009:1 122
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to HPV-infected cells is a cellular one and few viral-specific 
antibodies are produced. Only 50% of naturally infected 
women make antibodies against HPV and the antibodies 
are not always neutralizing. The vaccine appears to provide 
higher antibody levels than that observed in naturally 
occurring exposure by a factor of 12 to 26 and immunity has 
been demonstrated through 3 years post vaccination.32 The 
observation of protection at a time when antibody levels have 
reached a plateau is encouraging for long-term protection.
Pivotal vaccine studies
The major quadrivalent HPV recombinant vaccine trials will 
be discussed below in considerable detail. It is noteworthy 
to mention that Gardasil® induces a sustained immune 
response among vaccinated subjects and that furthermore 
it is virtually 100% effective in preventing type-specific 
(HPV types 6, 11, 16 and 18) cervical, vulvar, and vaginal 
lesions provided there is no type-specific viral DNA present 
on the cervix at the time of vaccination and the patient is sero-
negative to these types at the time of vaccination. The studies 
are therefore presented in the context of the “perfect popula-
tion” which includes subjects naïve to vaccine-specific HPV 
and analyzed in a type-specific manner with nearly 100% 
efficacious results. The other population studied is the “real 
world” which includes subjects naïve to HPV infections, those 
with current infections, as well as those previous infections. 
In this population the quadrivalent recombinant HPV vaccine 
significantly reduced the incidence of type-specific lesions 
including CIN/AIS and external genital warts.
The HPV vaccine trials utilized cervical intra-epithelial 
neoplasia 2 and 3 (CIN 2/3) and AIS as surrogate markers for 
prevention of cervical cancer as well as efficacy endpoints 
to assess prevention of cervical cancer. In addition, cases of 
vulvar and vaginal intraepithelial neoplasia 2 and 3 (VIN 
and VaIN 2/3) were efficacy endpoints to assess prevention 
of HPV-related vulvar and vaginal cancers. Observation for 
external genital warts was the efficacy endpoints for preven-
tion of genital warts. Efficacy was assessed in 4 placebo-
controlled, double-blind, randomized phase II and phase III 
clinical trials. The placebo administered was an amorphous 
aluminum hydroxyphosphate sulfate (AAHS) and was the 
adjuvant used in the quadrivalent vaccine. The first study in 
the development of HPV vaccine was the proof of principle 
trial.33 This landmark study demonstrated that subjects receiv-
ing three vaccinations with a monovalent HPV 16 VLP on 
day 1, month 2 and month 6 demonstrated protection from 
persistent HPV 16 infection as well as from HPV 16-related 
CIN. In the study, 2392 women between the ages of 16 and 
23 from 16 centers in the US were randomly assigned to 
receive either vaccine developed by Merck & Co. Research 
Laboratories consisting of 40 µg of highly purified VPL 
(empty capsids) of  the L1 polypeptide of  HPV 16 or placebo. 
Young women enrolled in the study were sexually active or 
planned to become sexually active in the near future. The 
subjects were not pregnant or planning to become pregnant 
in the near future and did not have a history of abnormal 
Pap test or had not had more than 5 male sexual partners 
during their lifetime. Out of the 2392 women enrolled, 
1533 subjects were included in the primary analysis. The 
subjects were studied for a median of 17.4 months. After 
adjusting for lost to follow-up and eliminating women with 
evidence of prior HPV 16 infections, 768 women received 
all three doses of vaccine and 765 women received placebo. 
None of the vaccinated women demonstrated persistence 
of HPV 16 infection compared to 41 women in the placebo 
group. Persistence was defined as testing positive for HPV 
16 on 2 consecutive visits. In this study 9 cases of CIN related 
to HPV 16 were detected in the placebo group while none 
were observed in the vaccine recipients. A follow-up study 
of the proof of principal monovalent HPV 16 phase II clini-
cal trial extended the follow-up phase to 48 months.34 This 
study compared 755 vaccinated women having completed 
all 3 vaccines to 750 women who had received placebo. 
There were 7 cases of persistent infection in the vaccinated 
women compared to 111 in the placebo group, representing 
94% efficacy. This trial also studied the development of HPV 
16-related CIN lesions in the same population and found no 
cases of CIN in the vaccinated women compared to 12 cases 
in the placebo group, representing 100% efficacy (Table 1).
The second phase II clinical trial evaluated all com-
ponents of the quadrivalent vaccine, HPV 6, 11, 16, and 
18 (Table 2).35 The purpose of the study was to assess the 
efficacy of the vaccine via a composite primary endpoint of 
persistent infection associated with HPV types 6, 11, 16, 18, 
or cervical or external genital disease (ie, persistent HPV 
infection, HPV detection at the last recorded visit, CIN, 
cervical cancer, or external genital lesions caused by the 
HPV types in the vaccine).
This study enrolled 552 women ages 16 to 23 years 
recruited from US, Brazil, and Europe with the following 
characteristics: none were pregnant, all had a negative his-
tory of abnormal Pap smears, and all had a lifetime history 
of 4 or less male sexual partners. Women with previous 
HPV infection were not excluded from the study. Of the 
552 women, 277 were assigned to vaccination and 275 were 
assigned to placebo. Women receiving the vaccine were International Journal of Women’s Health 2009:1 123
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given 20 µg type 6, 40 µg type 11, 40 µg type 16, and 20 µg 
type 18, with 225 µg aluminum adjuvant via intramuscular 
injection at day 1 then at 2 and 6 months. This study showed 
significant protection from persistent infection by vaccinated 
types in subjects vaccinated per protocol compared to placebo 
as well as 100% protection from the development of CIN 
caused by HPV 6, 11, 16, and 18 in vaccinated subjects who 
were not infected with these types at first vaccination. Effi-
cacy in prevention of genital warts caused by HPV 6 and 11 
was reported as 100% in the vaccinated subjects (Table 3).
Villa et al36 studied a subset of 241 patients from this 
population for a total of 5 years. The primary endpoint was 
the combined incidence of persistent infection or genital 
disease due to HPV 6, 11, 16, or 18, or HPV DNA detec-
tion at the last recorded visit, or detection of HPV DNA in 
biopsies of diagnosed cervical, vulvar, vaginal dysplasia, 
or genital warts. The combined incidence of HPV 6-, 11-, 
16-, 18-related persistent infection or disease was reduced 
by 96% in the vaccinated population. There were 2 cases of 
persistent HPV infection in the vaccinated group versus 46 
in the placebo group. There were no cases of CIN or genital 
warts related to the vaccinated HPV types in the vaccinated 
group versus 6 cases in the placebo group. Immunity in the 
vaccinated group remained above what is observed with 
natural exposure during the 5 years.
The next studies were phase III clinical trials-Future I37 
and Future II.38 Future I studied 5455 women aged 16 to 
24 years to assess the efficacy of the quadrivalent vaccine to 
prevent HPV-related anogenital disease. The primary aim of 
this trial was to determine vaccine efficacy in reducing the 
combined incidence of anogenital warts, vulvar or vaginal 
intraepithelial neoplasia grades 1–3, or vulvar or vaginal can-
cers associated with HPV types 6, 11, 16, and 18. A secondary 
aim was to observe whether the administration of vaccine 
reduced the combined incidence of CIN grades 1–3, AIS, 
or cervical cancer associated by vaccine type HPV. The 
study randomized a total of 5455 women into 2 groups, 
2723 receiving vaccine per protocol and 2732 receiving 
placebo The results of this trial showed the vaccine was 
100% effective in preventing external anogenital disease and 
demonstrated 100% efficacy in preventing CIN grades 1–3 
or AIS with HPV types 6, 11, 16, and 18. In the intention to 
treat (ITT) population of this study which included subjects 
with prevalent infection or disease by vaccine type and non-
vaccine types of HPV , vaccination reduced the incidence of 
vulvar, vaginal, or external anogenital disease regardless of 
causal HPV types by 34% and of cervical lesions regardless 
of causal HPV types by 20%. Future II was a multinational, 
prospective, double-blind, placebo-controlled trial with more 
than 12,000 subjects between the ages of 15 and 26 years who 
reported no more than 4 lifetime sexual partners. The subjects 
were randomized and assigned to receive 3 doses of vaccine 
or placebo. Sixty-five percent of participants were European 
and 26% were from Latin America. At baseline, cervical 
cytology was abnormal in 11% of both groups with 16% 
having evidence of infection with HPV 16 and 7% having 
evidence of infection with HPV 18. The mean duration of 
follow-up in the interim analysis used to support licensure 
was 3 years and the analysis of the completed 4-year trials 
will soon be published. The primary efficacy analysis was 
performed in subjects not having evidence of either HPV 
16 or 18 infections through 1 month after the third dose 
of the vaccine. These subjects were referred to as “HPV 
susceptible” per protocol. The primary composite endpoint 
was CIN 2 or 3, AIS, or cervical cancer related to HPV types 
16 or 18. The results of the trial demonstrated 98% efficacy 
in HPV-susceptible subjects (Table 4). However, the efficacy 
of the vaccine was lower (44%) for CIN 2 or 3 due to the 
vaccine-specific types in the overall population (also referred 
Table 1 Monovalent HPv 16 vLP vaccine trial
Population HPV 16 L1 VLP AAHS
HPv 16 persistence N Cases N Cases
17.4-month study 768 0 765 41
48-month study 755 7 750 111
HPv 16-related CIN
17.4-month study 768 0 765 9a
48-month study 755 0 750 12
aOf the 41 patients in the 17.4-month study of the AAHS group, 9 developed HPv 
16-related CIN.
Abbreviations:   AAHS, amorphous aluminum hydroxyphosphate sulfate; CIN, cervical 
intraepithelial neoplasia; HPv, human papillomavirus; N, number of patients vaccinated 
or receiving;   AAHS, respectively;   vLP,  viral-like particles.
Table 2 Summary of phase II clinical trial
vaccine type HPv 6, 11, 16, and 18 vLP L1 capsid component
Concentration 20 µg HPv 6
40 µg HPv 11
40 µg HPv 16
20 µg HPv 18
Dose 0.5 mL intramuscular
Sites US, Brazil, europe
Primary 
endpoint
Combined incidence of persisitent HPv infection and 
genital disease due to vaccine type HPv
Trial size 552 women (277 vaccinated, 275 placebo)
Abbreviations: HPv, human papillomavirus;    vLP,  viral-like particles.International Journal of Women’s Health 2009:1 124
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to as the ITT population which included subjects naïve to 
HPV 16/18 and subjects infected with HPV 16/18 or other 
types at day 1). In this group there was an 18% reduction in 
CIN 2/3 or AIS due to any HPV type.
Additional studies have been undertaken to specifically 
evaluate VIN 2/3 and VaIN 2/3 which, as previously stated, 
are considered the immediate precursors of HPV-related 
vulvar and vaginal cancers. One study was a combined 
analysis of 3 randomized clinical trials and evaluated the 
effect of a prophylactic quadrivalent human papillomavirus 
L1 virus-like particle vaccine on the incidence of high-
grade vulvar intraepithelial neoplasia (VIN 2/3) and high 
grade vaginal intraepithelial neoplasia (VaIN 2/3) associ-
ated with HPV types 16 and 18, as well as its effect on 
the overall rates of such lesions.39 The combined analysis 
included 18,174 women between the ages of 16 and 26 years 
randomized to either vaccine or placebo at day 1, and 
months 2 and 6. Patients underwent comprehensive anogeni-
tal exams at day 1, month 7, and every 6 to 12 months for 
up to 48 months. The subjects were divided into 3 groups or 
populations for analysis of efficacy at an average of 3 years 
after administration of dose 1. The first group was the “per 
protocol susceptible group.” This group included 7811 vac-
cinated subjects and 7785 placebo subjects. This population 
was evaluated starting at month 7 and included those subjects 
who had received all 3 doses of vaccine or placebo within 
12 months, and were seronegative and HPV DNA negative by 
polymerase chain reaction (PCR) for HPV 16 or HPV 18 at 
day 1. The subjects in this population also remained negative 
by PCR for the same HPV types through month 7 and had 
no major protocol violations. Subjects were included even if 
results of cervical cytological exam at day 1 were abnormal. 
In this population, the recombinant quadrivalent vaccine was 
100% effective in preventing VIN 2/3 or VaIN 2/3 by the 
vaccine-specific types. In the placebo groups, 15 cases of 
these precancerous conditions were observed. The second 
group evaluated was referred to as the “unrestricted suscep-
tible population”. They were evaluated starting after day 1 
with consideration of variable vaccine dose intervals and 
included subjects who were in the per protocol susceptible 
analysis as well as women with protocol violations. In this 
group, the vaccine had 97% efficacy in prevention of VIN 2/3 
or VaIN 2/3 by vaccine specific types. Only 1 case was noted 
in the vaccine group versus 29 in the placebo group. All 
vaccinated subjects were included in an analysis referred to 
as an ITT general study analysis. The analysis started after 
day 1 and included all women, including those with evi-
dence of infection and genital disease associated with HPV 
16 and/or HPV 18 prior to vaccination. In this analysis the 
incidence of VIN 2/3 or VaIN 2/3 by vaccine specific types 
in the vaccinated group was reduced by 71%. Nine cases 
were observed in the vaccinated subjects versus 31 cases in 
the placebo groups. In the ITT group, vaccine efficacy was 
reported as 49%, irrespective of causal HPV type as well 
irrespective of whether or not HPV DNA was detected in 
the lesion. In the ITT group there was 1 case of squamous 
cell perianal carcinoma in a vaccinated subject 18 months 
after completion of the vaccine series.
Another combined analysis of the quadrivalent HPV L1 
virus-like particle recombinant vaccine versus placebo evalu-
ated the rates of external genital disease including genital 
warts, VIN, VaIN, vulvar cancer, and vaginal cancer in 3 
trials including Future I and Future II.40 In the per protocol 
analysis the quadrivalent HPV recombinant vaccine was 
found to be 99% effective in preventing HPV 6-, 11-, 16-, 
or 18-related genital warts, and VIN or VaIN of any grade. 
In summary, when reviewing these pivotal quadrivalent 
HPV recombinant vaccine trials as well as when reviewing 
Table 3 Phase II clinical trial
Population Gardasil® Placebo Efficacy (95% CI)
Persistent infection
HPv 6 0 13 100.0 (68.0, 100.0)
HPv 11 0 0 NS
HPv 16 3 21 86.0 (54.0, 97.0)
HPv 18 1 9 89.0 (21.0–100.0)
HPv 6-,11-, 16-, or 18-related 
CIN (CIN 2, CIN 2/3) or AIS
0 3 100.0 (–138.4, 100.0)
HPv 6-,11-,16- or 18-related 
genital warts
0 3 100.0 (–139.5, 100.0)
Note: Populations were per protocol.
Abbreviations:   AIS, adenocarcinoma in situ of the cervix; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; NS, not clinically significant.International Journal of Women’s Health 2009:1 125
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meta-analyses of vaccine trials conducted,41 a significant 
reduction in high grade lower genital tract disease caused 
by vaccine type HPV types is observed particularly in 
HPV-susceptible subjects. An interesting and attractive find-
ing in some vaccine trials has been cross-protection. Since 
HPV types have varying degrees of genetic relatedness, it 
had been theorized that cross-protection to phylogenetically 
similar non-vaccine HPV types may be observed in vacci-
nated women. The additional protection against non-vaccine 
types HPV types may prevent even more HPV-associated 
malignancies than initially predicted, especially against HPV 
45 which is the third most common HPV type implicated in 
cervical carcinoma and cervical adenocarcinoma.42 Cross-
protection remains a theoretical benefit at this time and 
remains under investigation. Support of vaccination with the 
quadrivalent HPV recombinant vaccine in early adolescence 
was arrived at based on bridging studies than proved that 
vaccine-induced neutralizing antibody responses in 10- to 
15-year-old girls and boys were non-inferior and in fact 
higher than those observed in 16- to 23-year-old females.43 
Based on this immunogenicity bridging, the efficacy of 
Gardasil® in 9- to 15-year-old girls is inferred.
Safety data
Safety data from the quadrivalent HPV vaccine trials have 
been evaluated and appear extremely favorable. In the 
4 placebo-controlled trials local and systemic events were 
monitored. Approximately 83% of vaccine recipients 
reported local site reactions within 5 days after any dose 
compared to 77% of subjects receiving aluminum adju-
vant placebo. The most common local reactions reported 
included pain, swelling, or redness at the injection site and 
the majority of these reactions were mild to moderate in 
severity. Systemic reactions were also monitored in the 
4 placebo-controlled trials. Both vaccinated and placebo 
recipients had comparable systemic adverse events within 
15 days after any dose (59% versus 60%). The most com-
mon systemic events in both Gardasil® and placebo groups 
included headache and nausea.
Serious adverse events were comparable in number between 
Gardasil® recipients and placebo groups (136 versus 125). 
There were 10 deaths in subjects receiving Gardasil® and 
7 among placebo recipients. The most common cause of death 
was motor vehicle accident (4 in Gardasil® group versus 3 in 
placebo group) followed by suicide/overdose (1 in Gardasil 
group versus 2 in placebo group) and thromboembolism 
(1 case in each group). Rare events included 2 cases of sepsis 
in the Gardasil® group, 1 case occurring 395 days post dose 
3 and another occurring in a subject 625 days post dose 3. 
Additionally, 1 case of pancreatic cancer was reported in 
the Gardasil® group 578 days following dose 3, and 1 case 
of arrhythmia 27 days post dose 1 in a young male with a 
family history of arrhythmia. In the placebo group 1 case of 
asphyxia was reported.
The pregnancy outcomes in pregnant subjects receiv-
ing either Gardasil® or placebo were comparable. Gardasil® 
recipients had similar rates of live births (62%) compared to 
placebo recipients (60%). The rate of spontaneous abortion was 
also similar between the 2 groups and approximated 25%. The 
rate of adverse events and occurrences in pregnant subjects is 
similar between the 2 groups and included conditions leading 
to cesarean section, premature labor, and pre-eclampsia. Con-
genital anomalies were also monitored and the incidence was 
similar in both vaccinated and placebo groups. Data on infants 
of nursing mothers have also been evaluated and there was a 
higher proportion of cases of respiratory illnesses and gas-
troenteritis among infants of mothers administered Gardasil® 
during the time they were breast-feeding: 12 cases of respira-
tory illnesses in the Gardasil® group compared to 6 cases in the 
placebo group, and 5 cases of gastroenteritis in the Gardasil® 
group compared to 2 cases in the placebo group. All cases of 
respiratory events occurred in the Latin American region and 
the majority of the subjects received further vaccine without 
additional observed respiratory events in their infants. Due to 
the small number of events and the variable times between vac-
cination and events, a definitive association could not be made. 
The post-market recommendations noted in the package insert 
advise that the vaccine is not recommended for use in women 
known to be pregnant and urges caution with administration 
to nursing mothers. Merck & Co. has established a pregnancy 
registry in the US to prospectively collect data on spontaneously 
reported exposures to Gardasil® during pregnancy.
Since introduction of the quadrivalent HPV recombinant 
vaccine on June 8, 2006 in the US, the FDA and the Vaccine 
Adverse Event Reporting System (VAERS) have been 
monitoring the safety of the vaccine.44 VAERS receives uncon-
firmed reports of possible side effects. The FDA analyzes 
adverse events and possible side effects associated with 
individual lots or batches of vaccine to identify any unusual 
patterns. To date no unusual patterns have been observed in the 
FDA’s review of the quadrivalent HPV recombinant vaccine.
Over 16 million doses of Gardasil® have been given in 
the US to date. Data received by VAERS on post-vaccination 
events may or may not be caused by vaccination. As of June 30, 
2008 there have been 9749 VAERS reports of adverse events 
following Gardasil® vaccination. Ninety-four percent of these International Journal of Women’s Health 2009:1 126
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events have been classified as non-serious events and 6% have 
been classified as serious events. The non-serious events have 
included syncope, pain at injection site, headache, nausea, and 
fever. Falls related to syncope have the potential for injury; 
therefore recommendations are to keep patients seated for up 
to 15 minutes post vaccination for observation. Twenty deaths 
have been reported to VAERS. A common pattern to the deaths 
was not identified, suggesting they were not caused by the 
vaccine. In cases where autopsy, death certificate, or medical 
records were available, none of the deaths were attributable to 
the vaccine. Another serious report has been post-vaccination 
cases of Guillain-Barré syndrome (GBS). GBS is a rare neu-
rological disorder causing muscle weakness. The FDA and 
VAERS have reviewed reports of GBS submitted to VAERS 
and have concluded that there is no evidence that Gardasil® 
has increased the rate of GBS above that expected in the 
population. In a recent review of GBS following Gardasil® 
vaccination, investigators found 36 cases of GBS reported in 
girls and women ages 13 to 50.45 Gardasil® was the only vac-
cine administered in 60% of patients while 40% of patients 
had received Gardasil® in combination with other vaccines. 
The incidence of GBS was calculated as 7.0 per million in the 
post-Gardasil® population compared to 4.0–10.0 per million in 
the general population. Another serious safety concern about 
the quadrivalent HPV vaccine is thromobembolic events. 
It appears that individuals experiencing these disorders post 
vaccination had risk factors for blood clots such as the use 
of oral contraceptive pills. This issue continues to be studied 
through the Vaccine Safety Datalink (VSD) project, which 
is a collaborative effort between the Centers for Disease 
Control and managed care organizations. Anaphylaxis was 
not reported in any of the vaccine trials. However since the 
2007 Australian implementation of the national human papil-
lomavirus vaccination program, which provides free HPV 
vaccinations to females ages 12 to 26 years, a small rate of 
anaphylaxis has been observed.46 There have been 269,680 
HPV vaccines administered in schools with an anaphylaxis 
incident rate of 2.6 per 100,000 doses. Possible explanations 
for the difference in vaccine study groups and the Australian 
experience may be due to sample size. Some authorities believe 
that the anaphylaxis reaction in the Gardasil® vaccine may be 
related to the presence of polysorbet 80 which is a stabilizer 
with a known history of causing anaphylaxis or generalized 
hypersensitivity reactions.
Other pressing issues
Thus far we have reviewed the excellent efficacy of the 
recombinant quadrivalent HPV vaccination in the prevention 
Table 4 Analysis of efficacy of Gardasil® in the PPea population of 16- through 26-year-old women for vaccine HPv types
Population Gardasil® AAHS control % Efficacy (95% CI)
N Number 
of cases
N Number  
of cases
HPV 16- or 18-related  
CIN 2/3 or AIS
Future I 2201 0 2222 36 100.0 (65.1, 100.0)
Future II 5306 2 5262 63 96.9 (88.2, 99.6)
HPV 6-,11-,16-, of 18-related  
CIN (CIN 1, 2/3) or AIS
Future I 2241 0 2258 77 100.0 (95.1, 100.0)
Future II 5388 9 5374 145 93.8 (88.0, 97.2)
HPV 16- or 18-related   VIN 2/3
Future I 2219 0 2239 6 100.0 (14.4, 100.0)
Future II 5322 0 5275 4 100.0 (-50.3, 100.0)
HPV 16- or 18-related   VaIN 2/3
Future I 2219 0 2239 5 100.0 (-10.1, 100.0)
Future II 5322 0 5275 4 100.0 (-50.3, 100.0)
HPV 6-,11-,16-, or 18-related 
genital warts
Future I 2261 0 2279 58 100.0 (93.5, 100.0)
Future II 5404 2 5390 132 98.5 (94.5, 99.8)
aPPe population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve 
(PCr negative and seronegative) to the relevant HPv type(s) prior to dose 1 and through 1 month post dose 3.
Abbreviations:   AAHS, control, amorphous aluminum hydroxyphosphate sulfate;    AIS, adenocarcinoma in situ of the cervix; CI, confidence interval; CIN, cervical intraepithelial 
neoplasia; HPv, human papillomavirus; N, number of subjects with at least 1 follow-up visit after month 7;   vaIN, vaginal intraepithelial neoplasia;   vIN, vulvar intraepithelial 
neoplasia.International Journal of Women’s Health 2009:1 127
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of the cervical, vulvar and vaginal precancerous states and 
cancers noting that protection seems superior in the sexually 
naïve and HPV susceptible recipient. The impressive safety 
data during vaccine trials as well as in the post-marketing 
era has also been reviewed. Remaining issues of significant 
importance are many and include duration of immunity and 
the possibility of the need for “booster” immunization with 
attendant adjustment of cost-effective formulas for this added 
expense. Studies have shown quadrivalent HPV recombi-
nant vaccine immunity through 5 years47 and Merck & Co. 
have committed to continue monitoring immunogenicity 
through the Nordic Long-term Follow-up Study. Therefore 
the optimal age for vaccination as well as cut-off age for 
vaccination must be wisely determined with priority for the 
sexually uninitiated adolescent. Gardasil® has been approved 
in over 80 countries, most recommending vaccination in early 
adolescence. In the US, the Advisory Committee on Immu-
nization Policies recommends vaccinating 11- to 12-year-
olds but allows vaccination as early as 9 years of age with 
“catch-up” vaccines until age 26. It is of utmost importance to 
realize that secondary prevention of cervical cancer through 
continued Pap smear screening cannot be abandoned in 
vaccinated populations. As previously mentioned, HPV types 
16 and 18 appear responsible for 70% of cervical cancers but 
the remaining 30% of cervical cancers are due to other HPV 
types. There are reported cases of cervical cancers48 and also 
of vulvar carcinoma in vaccinated women, highlighting the 
importance of continued surveillance with cytology screening 
and routine gynecological exams to monitor for cervical and 
genital disease regardless of cause. The exact nature of 
cross-protection against other non-vaccine HPV types must 
be investigated as this may provide wider protection than 
previously thought. The goal of vaccination ideally should be 
to provide lifelong protection but others view the role of the 
vaccine in the context of reducing disease and maintaining 
effectiveness during ages of peak oncogenic HPV exposure. 
Male vaccination is also a controversial topic. Vaccination 
for HPV types 16/18 in combination with annual Pap smear 
screening commencing at age 18 was estimated in a Markov 
model to offer the largest overall reduction in cancer inci-
dence and mortality at a cost of US$236,250 per life-year 
gained for female-only vaccination.49 The addition of male 
vaccination has been projected to further reduce cervical 
cancer incidence by only 2.2% at an incremental cost-
effectiveness ratio of US$442,039/quality-adjusted life-year 
(QALY). Some countries such as Australia have elected to 
vaccinate males while others have not. However, no country 
has included male vaccination in its publicly financed 
immunization programs. Several arguments have been 
posed to support male vaccination, including prevention of 
non-genital HPV-related disease, prevention of genital warts, 
and reduction of disease through herd immunity. In men, 
about 50% of penile cancers are linked to oncogenic HPV .50 
In December 2008 Merck & Co. presented the FDA with 
data on male vaccination with Gardasil® evaluating penile 
intraepithelial neoplasia, and the FDA may update recom-
mendations for males based on these data. Another area of 
discussion has been the concern that although prophylactic 
HPV vaccines show protection in genital premalignant 
disease, they have not been studied long enough to definitely 
demonstrate prevention of genital malignancy, particularly 
cervical cancer. A limitation to definitive proof is the lengthy 
period of time between HPV exposure and development 
of cervical cancer. Phase III clinical studies are underway 
enrolling sufficient numbers of subjects to guarantee enough 
power to enable evaluation of data on efficacy of vaccina-
tion against carcinoma in situ of the cervix and higher by 
the year 2020.51 Another area of concern is niche selection 
which is the possibility that as HPV 16 and 18 are eliminated, 
other currently less common oncogenic types will become 
more pervasive and lead to vaccine modification in order to 
address disease from those types. Acceptance of the vaccine 
represents an obstacle. Resistance to the HPV vaccine in 
some cases is based on religious objections from groups that 
believe the availability of a vaccine that prevents a sexually 
transmitted disease is a license to engage in premarital sex. 
In the United States groups with this philosophy as well 
as groups with the concern that the HPV vaccines under-
mine abstinence-only programs and promote promiscuity 
have strongly objected to mandated vaccination programs 
despite the proposal of “opt-out” options. Unfortunately, 
wide acceptance and availability of vaccines may not come to 
fruition unless there are government guidelines and programs 
in place to not only require the vaccine but also to make it 
available to those who cannot afford it. Another important 
role of government which is linked to acceptance is public 
education in matters related to disease prevention. It has 
been shown that in terms of vaccine acceptance, developing 
public health messages that focus on HPV infection and 
its link to cervical cancer to educate parents may have the 
greatest impact on improving the uptake of the vaccine.52 
By far the greatest challenge pertaining to the quadrivalent 
HPV recombinant vaccine is its affordability particularly for 
developing nations where burden of disease is the highest, 
secondary screening programs are suboptimal and large 
gaps in education exist. Hopefully, organizations such as International Journal of Women’s Health 2009:1 128
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the Global Alliance for Vaccines and Immunization (GAVI 
Alliance), which provides technical assistance and financial 
support for vaccines in countries with gross national income 
of less than US$1,000 per capita as well as China, India, 
and Indonesia, will make an impact in the most distressed 
areas of the globe. Currently the GAVI Alliance has made a 
commitment to provide girls in struggling nations with HPV 
vaccines and is trying to overcome funding shortages to do so. 
It is important to view the prophylactic HPV vaccines as an 
important part of the multifaceted strategy to prevent cancers 
of the cervix, vagina, and vulva. Other important parts of 
the strategy must include continued secondary prevention 
programs and education on lifestyle modifications to reduce 
risks and disease.53 Despite unanswered questions and differ-
ing opinions as to how to best utilize the quadrivalent HPV 
recombinant vaccines, we must recognize that we have an 
invaluable tool in our hands – a tool that could eventually 
lead to disease eradication. Time will tell if we are wise and 
visionary stewards of this medical legacy.
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